CN111888395A - Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment - Google Patents
Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment Download PDFInfo
- Publication number
- CN111888395A CN111888395A CN202010738543.9A CN202010738543A CN111888395A CN 111888395 A CN111888395 A CN 111888395A CN 202010738543 A CN202010738543 A CN 202010738543A CN 111888395 A CN111888395 A CN 111888395A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- root
- scapulohumeral periarthritis
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010034464 Periarthritis Diseases 0.000 title claims abstract description 73
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 40
- 241000218176 Corydalis Species 0.000 claims abstract description 35
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 31
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 31
- 241000903946 Clematidis Species 0.000 claims abstract description 27
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 27
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 21
- 241001106477 Paeoniaceae Species 0.000 claims abstract description 21
- 241000218158 Clematis Species 0.000 claims abstract description 19
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 18
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 13
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 238000000227 grinding Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 230000001376 precipitating effect Effects 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 2
- 241000212322 Levisticum officinale Species 0.000 claims 1
- 239000001645 levisticum officinale Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 238000002474 experimental method Methods 0.000 abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 206010041591 Spinal osteoarthritis Diseases 0.000 abstract description 4
- 208000036319 cervical spondylosis Diseases 0.000 abstract description 4
- 208000005801 spondylosis Diseases 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 20
- 210000003205 muscle Anatomy 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 241000283977 Oryctolagus Species 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 210000000323 shoulder joint Anatomy 0.000 description 9
- 206010028836 Neck pain Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000002639 bone cement Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000009916 joint effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000002351 wastewater Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 241001105098 Angelica keiskei Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004095 humeral head Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 239000008727 tongluo Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The disclosure relates to a pharmaceutical composition for treating scapulohumeral periarthritis, and particularly provides a pharmaceutical composition, a preparation method thereof and application thereof in scapulohumeral periarthritis treatment. On the one hand, the application of a pharmaceutical composition in preparing a medicine for treating scapulohumeral periarthritis is provided, and the pharmaceutical composition is as follows: 1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber, 3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae and 4-25 parts of notopterygium root. In another aspect, a pharmaceutical composition for treating scapulohumeral periarthritis is provided, wherein the pharmaceutical composition comprises: 15-45 parts of pseudo-ginseng, 8-30 parts of ligusticum wallichii, 2-7 parts of corydalis tuber, 3-7 parts of white paeony root, 5-11 parts of clematis root, 5-9 parts of kudzu root and 4-25 parts of notopterygium root. Experiments show that the Mingren Jingtongtian tablets for treating cervical spondylosis in the prior art have the curative effect on the treatment of scapulohumeral periarthritis, but have the effect on the diabetic scapulohumeral periarthritis inferior to that of a new pharmaceutical composition with the changed proportion.
Description
Technical Field
The disclosure relates to a pharmaceutical composition for treating scapulohumeral periarthritis, and particularly provides a pharmaceutical composition, a preparation method thereof and application thereof in scapulohumeral periarthritis treatment.
Background
The statements herein merely provide background information related to the present disclosure and may not necessarily constitute prior art.
Scapulohumeral periarthritis, commonly called congealing shoulder and fifty shoulder. The pain of the shoulder is gradually produced, the pain is gradually increased at night, the activity function of the shoulder joint is limited and gradually increased, and the pain is gradually relieved after reaching a certain degree until the shoulder joint is completely restored to be the chronic specific inflammation of the shoulder joint capsule and the surrounding ligaments, tendons and bursa. Periarthritis of shoulder is a common disease with pain and difficulty in movement of shoulder joints as main symptoms.
In the prior art, the treatment method of the scapulohumeral periarthritis is generally considered to be blood circulation promoting and blood stasis removing, and common blood circulation promoting and blood stasis removing medicines for treating traumatic injuries are generally adopted for treatment, such as a Wantong muscle and bone patch, a Tongluo Qutong paste, a Musk tiger bone patch and the like.
The applicant has conducted a certain research on the treatment medicine for cervical spondylosis in 2003 and applied for patent CN03112032.6, and at present, the patent product has been made into a medicine with the trade name of "minren jingtao tablet", which has a good treatment effect on cervical spondylosis, but neither the applicant nor other persons skilled in the art have searched for the "minren jingtao tablet" in other applications except for cervical spondylosis.
Disclosure of Invention
The traditional Chinese medicine composition aims at solving the problem that the prior art generally adopts blood circulation promoting and stasis removing medicines to treat scapulohumeral periarthritis, has a certain curative effect, but has a poor general effect on diabetic scapulohumeral periarthritis.
In one or more embodiments of the present disclosure, there is provided a use of a pharmaceutical composition for preparing a medicament for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber, 3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae and 4-25 parts of notopterygium root;
or 2-10 parts of pseudo-ginseng, 5-15 parts of ligusticum wallichii, 3-10 parts of corydalis tuber, 5-15 parts of radix paeoniae alba, 8-20 parts of radix clematidis, 5-15 parts of radix puerariae and 8-20 parts of notopterygium root;
or 2-3 parts of pseudo-ginseng, 7-8 parts of ligusticum wallichii, 5-6 parts of corydalis tuber, 7-8 parts of radix paeoniae alba, 10-11 parts of radix clematidis, 7-8 parts of radix puerariae and 10-11 parts of notopterygium root;
or 2.3 parts of pseudo-ginseng, 7.6 parts of ligusticum wallichii, 5.4 parts of corydalis tuber, 7.6 parts of white paeony root, 10.5 parts of clematis root, 7.6 parts of kudzu root and 10.5 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 15-45 parts of pseudo-ginseng, 8-30 parts of ligusticum wallichii, 2-7 parts of corydalis tuber, 3-7 parts of white paeony root, 5-11 parts of clematis root, 5-9 parts of kudzu root and 4-25 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 20-40 parts of pseudo-ginseng, 10-20 parts of ligusticum wallichii, 3-5 parts of corydalis tuber, 5-7 parts of radix paeoniae alba, 9-10 parts of radix clematidis, 5-7 parts of radix puerariae and 4-17 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 25-35 parts of pseudo-ginseng, 10-15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6-7 parts of radix paeoniae alba, 9 parts of radix clematidis, 6-7 parts of radix puerariae and 9-10 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 30 parts of pseudo-ginseng, 15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6 parts of white paeony root, 9 parts of clematis root, 6.3 parts of kudzu root and 9.7 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, comprising the steps of:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting the white paeony root with the water solution distilled in the step (2), and collecting and concentrating filtrate for later use;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol;
(6) and (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
One of the above technical solutions has the following advantages or beneficial effects:
1) according to the first aspect of the disclosure, the application of the Mingren Jingtong tablet in the aspect of scapulohumeral periarthritis treatment is researched, as can be seen from fig. 1, in wind-cold-dampness scapulohumeral periarthritis, the Mingren Jingtong tablet and the medicine with the improved formula thereof have better treatment effects, are similar to those of Wantong muscle and bone patches in the prior art, and develop the application of the Mingren Jingtong tablet.
2) The inventor discovers that the blood circulation promoting and blood stasis removing medicines are generally adopted to treat the scapulohumeral periarthritis in the prior art in the actual treatment process of the scapulohumeral periarthritis, and the problem of poor effect generally exists for the diabetic scapulohumeral periarthritis although the medicine has a certain curative effect. Therefore, the inventor tries to explore the application of the Mingren Jingtong tablet in the scapulohumeral periarthritis and finds that the Mingren Jingtong tablet has better effect than Wantong muscle and bone paste in the treatment of the diabetes type scapulohumeral periarthritis. In the second aspect of the disclosure, the formula and the formulation of the Mingren Jingtong tablet are optimized, namely, the proportion of pseudo-ginseng and rhizoma ligustici wallichii is improved in the formula aspect, the oral medicine is changed into the external medicine in the formulation aspect, and as can be seen from fig. 2, the effect of the pharmaceutical composition in the experiment 1 group is far better than that of other groups in the treatment of the diabetes type scapulohumeral periarthritis. Obviously, for the diabetes type scapulohumeral periarthritis, the mingren neck pain tablets and the Wantong muscle and bone paste have the old effect on the treatment of the scapulohumeral periarthritis, but are far inferior to the pharmaceutical composition described in the experiment 1 group. Therefore, the novel medicinal composition with the improved formula plays a greater role in the treatment of the diabetic scapulohumeral periarthritis, and therefore, the medicament with the improved formula can meet the treatment requirement of the diabetic scapulohumeral periarthritis.
3) The third aspect of the disclosure provides a preparation method of a medicament with an optimized formulation, and as can be seen from fig. 1-2, the effect of the pharmaceutical composition described in example 1 is better than that of the pharmaceutical compositions described in examples 3 and 4, it can be seen that the grinding of notoginseng and chuanxiong rhizome together has a matching relationship, and possibly the grinding of notoginseng and chuanxiong rhizome promotes the separation of components of each other, which is beneficial for the medicament to act. And the inventor thinks that the effect of the white paeony root is possibly conflicted in the process of matching the cold medicament and the warm medicament, and the white paeony root is decocted by the extraction waste water of the notopterygium root and the clematis root, so that the cold property of the white paeony root is slightly neutralized, and the absorption of the medicaments by a patient is facilitated.
4) The performance of the medicine is tested by taking the New Zealand rabbits as an animal model, the mode is generally accepted in the field of scapulohumeral periarthritis treatment, the New Zealand rabbits are treated by ice compress, wind-cold-dampness scapulohumeral periarthritis is simulated, and obviously, the medicine composition is mainly applied to rheumatoid scapulohumeral periarthritis.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this disclosure, illustrate embodiments of the disclosure and, together with the description, serve to explain the disclosure and not to limit the disclosure.
FIG. 1 shows the results of measurement of the content of 5-HT, IL-1. beta. and IL-10 in serum homogenate 2 weeks after the administration to New Zealand rabbits as described in example 5.
FIG. 2 shows the measurement results of the levels of 5-HT, IL-1. beta. and IL-10 in the serum homogenate 2 weeks after the SD rat described in example 6.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present invention without making any creative effort, shall fall within the protection scope of the present invention.
The diagnosis standard of the wind-cold-dampness scapulohumeral periarthritis disclosed by the invention is as follows: symptoms are: the pain stage is characterized by gradual reduction of shoulder joint activity, including outward rotation, inward rotation and outward expansion of the shoulder, which is most obvious in outward expansion function limitation, and the typical shoulder carrying phenomenon appears, even the shoulder serum atrophy appears in the shoulder, the symptoms above the remission stage are gradually relieved, and the shoulder joint activity is gradually recovered.
Laboratory examination, x-ray examination is negative, and osteoporosis is visible in patients with chronic diseases. The frozen shoulder is proved by the Lishi broadside shoulder line examination (from the inner edge of the humeral shaft to the upper edge of the scapula body along the humeral neck, head and through the scapula pelvis) when the line is not continuous, especially the axillary side edge of the glenohumeral joint and the humeral head move upwards, namely when the humeral shoulder line is positive.
The diagnosis standard of the diabetic scapulohumeral periarthritis disclosed by the disclosure is formulated by referring to the traditional Chinese medicine industry standard, traditional Chinese medicine disease diagnosis and treatment effect standard of the people's republic of China and the pain diagnosis and treatment science, and specifically, the diabetic scapulohumeral periarthritis has (1) the age of more than 50 years and the history of more than 6 years. (2) The history of symmetric pain in the shoulder joints is accompanied by limited movement for about 3 months. (3) There is no disease of heart, brain and kidney. (4) The fasting blood sugar of two groups of patients is less than or equal to 7.0mmol/L (126mg/dL), and the glycosylated hemoglobin is less than or equal to 8.0%.
The traditional Chinese medicine composition aims at solving the problem that the prior art generally adopts blood circulation promoting and stasis removing medicines to treat scapulohumeral periarthritis, has a certain curative effect, but has a poor general effect on diabetic scapulohumeral periarthritis.
In one or more embodiments of the present disclosure, there is provided a use of a pharmaceutical composition for preparing a medicament for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber, 3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae and 4-25 parts of notopterygium root;
or 2-10 parts of pseudo-ginseng, 5-15 parts of ligusticum wallichii, 3-10 parts of corydalis tuber, 5-15 parts of radix paeoniae alba, 8-20 parts of radix clematidis, 5-15 parts of radix puerariae and 8-20 parts of notopterygium root;
or 2-3 parts of pseudo-ginseng, 7-8 parts of ligusticum wallichii, 5-6 parts of corydalis tuber, 7-8 parts of radix paeoniae alba, 10-11 parts of radix clematidis, 7-8 parts of radix puerariae and 10-11 parts of notopterygium root;
or 2.3 parts of pseudo-ginseng, 7.6 parts of ligusticum wallichii, 5.4 parts of corydalis tuber, 7.6 parts of white paeony root, 10.5 parts of clematis root, 7.6 parts of kudzu root and 10.5 parts of notopterygium root.
Further, the preparation method of the pharmaceutical composition comprises the following steps:
(1) firstly, the pseudo-ginseng is crushed into 100-mesh and 120-mesh fine powder;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, collecting the distilled water solution in another container, decocting the residue with water for 1 hr, and filtering to obtain filtrate;
(3) decocting radix Puerariae and radix Paeoniae alba with water twice (2 hr for the first time and 1 hr for the second time), mixing the filtrate with the above two water solutions, concentrating, precipitating with ethanol, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(4) reflux-extracting rhizoma Ligustici Chuanxiong and rhizoma corydalis with ethanol, removing residue, recovering ethanol from the extractive solution, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(5) mixing the above two fluid extracts, adding Notoginseng radix powder, mixing, drying, pulverizing into fine powder, adding appropriate amount of rhizoma Peucedani, mixing, and spraying the volatile oil of Notopterygii rhizoma and radix Clematidis.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 15-45 parts of pseudo-ginseng, 8-30 parts of ligusticum wallichii, 2-7 parts of corydalis tuber, 3-7 parts of white paeony root, 5-11 parts of clematis root, 5-9 parts of kudzu root and 4-25 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 20-40 parts of pseudo-ginseng, 10-20 parts of ligusticum wallichii, 3-5 parts of corydalis tuber, 5-7 parts of radix paeoniae alba, 9-10 parts of radix clematidis, 5-7 parts of radix puerariae and 4-17 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 25-35 parts of pseudo-ginseng, 10-15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6-7 parts of radix paeoniae alba, 9 parts of radix clematidis, 6-7 parts of radix puerariae and 9-10 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a pharmaceutical composition for treating scapulohumeral periarthritis, the pharmaceutical composition comprising: 30 parts of pseudo-ginseng, 15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6 parts of white paeony root, 9 parts of clematis root, 6.3 parts of kudzu root and 9.7 parts of notopterygium root.
In one or more embodiments of the present disclosure, there is provided a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, comprising the steps of:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting the white paeony root with the water solution distilled in the step (2), and collecting and concentrating filtrate for later use;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol;
(6) and (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
Further, in the step (1), the pseudo-ginseng and the ligusticum wallichii are crushed into 100-120-mesh fine powder.
Further, in the step (3), the white paeony root is cut into small blocks and decocted for 4-4.5 hours.
Further, in the step (5), the concentrated extract is clear paste with the relative density of 1.50-1.55 at 50 ℃.
Example 1
The embodiment provides a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, which comprises the following steps:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together; pulverizing into 100 mesh fine powder.
(2) Extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting radix Paeoniae alba with the water solution distilled in step (2), cutting radix Paeoniae alba into small pieces, decocting for 4 hr, collecting filtrate, and concentrating;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol; concentrating to obtain fluid extract with relative density of 1.50 at 50 deg.C.
(6) And (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
Example 2
The embodiment provides a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, which comprises the following steps:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together; pulverizing into 120 mesh fine powder.
(2) Extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting radix Paeoniae alba with the water solution distilled in step (2), cutting radix Paeoniae alba into small pieces, decocting for 4.5 hr, collecting filtrate, and concentrating;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol; concentrating to obtain fluid extract with relative density of 1.55 at 50 deg.C.
(6) And (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
Example 3
This example provides a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, which is different from example 1 in that, in the step (1), notoginseng and chuanxiong rhizome are separately ground. The method comprises the following steps:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong respectively. Pulverizing into 100-120 mesh fine powder.
(2) Extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting radix Paeoniae alba with the water solution distilled in step (2), cutting radix Paeoniae alba into small pieces, decocting for 4-4.5 hr, collecting filtrate, and concentrating;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol; concentrating to obtain fluid extract with relative density of 1.50-1.55 at 50 deg.C.
(6) And (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
Example 4
The present example provides a method for preparing a pharmaceutical composition for treating scapulohumeral periarthritis, which is different from example 1 in that, in the step (3), white peony root is decocted with purified water. The method comprises the following steps:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together; pulverizing into 100-120 mesh fine powder.
(2) Extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting radix Paeoniae alba with purified water, cutting radix Paeoniae alba into small pieces, decocting for 4-4.5 hr, collecting filtrate, and concentrating;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol; concentrating to obtain fluid extract with relative density of 1.50-1.55 at 50 deg.C.
(6) And (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
Example 5
60 healthy New Zealand rabbits with the age of 6 months are selected, namely 30 male rabbits and 30 female rabbits, and each rabbit weighs 0.5kg for 3 seconds.
30 New Zealand rabbits were divided into 6 groups of 5 male rabbits and 5 female rabbits, wherein the 6 groups were a control group, a group of Mingren neck pain tablets, a group of Wantong bone and muscle patches, an experiment 1 group, an experiment 2 group and an experiment 3 group.
Establishing an animal model of wind-cold-dampness type scapulohumeral periarthritis: the right shoulders of the 60 new zealand rabbits were shaved and supined, the hind limb and the left forelimb were fixed on a rabbit table, and the upper arm of the left forelimb was fixedly connected with wHE-80 electric oscillators (manufactured by grain and oil machinery factories, east China Numbers of China-Ying). Shaking shoulder joint in parallel at a vibration amplitude of 1.5cm at a frequency division rate of 280 times, lasting 8 hours every day for 3 days; then fixing the rabbit in a rabbit cage in a supine manner; and (3) wetting the plastic bag with water, then applying an ice block on the right shoulder of the rabbit, replacing the plastic bag for 8 hours every day continuously for 3 days when the ice block is completely melted, and simulating the symptoms of the wind-cold-dampness scapulohumeral periarthritis to finish the establishment of the model.
The 6 test groups were treated as follows:
the control group was fed with the feed normally except that no treatment was performed.
Group of Mingren Jingtong tablets: grinding the Mingren Jingtong tablets into powder, weighing 0.16g each time, and feeding the New Zealand rabbits 4 times a day.
Wantong muscle and bone patch group: cutting commercially available Wantong muscle and bone paste into small pieces, and externally applying to the right shoulder of New Zealand rabbit, changing the dressing every 6 hours at 8:00-20:00 every day, and not changing the dressing within 8:00 period of 20: 00-day.
Experiment 1-3 groups: the ointments of examples 1,3 and 4 are respectively coated on the right shoulders of the rabbits, and the dressing change is carried out once every 6 hours at 8:00-20:00 every day, and the dressing change is not carried out within 8:00 period from 20:00 to the next day.
After 2 weeks, the index test was performed on the above 6 groups.
Index detection standard:
general state observation: observing the rabbit molding and the post-treatment shoulder swelling condition and the right forelimb activity condition, and whether special phenomena such as fever, depilation and the like exist.
Determination of the 5-HT content of serum homogenate: measuring by high performance liquid chromatography electrochemical detection technology.
Serum homogenate IL-1 β: the enzyme-linked immunoassay is used for determination.
Serum homogenate IL-10: the enzyme-linked immunoassay is used for determination.
The observations after 2 weeks were as follows:
general condition observation is carried out to find that: the right forelimb of the control group was significantly impaired in activity, the amount of activity was reduced, and 4 new zealand rabbits had significant swelling in the right shoulder. The group of Mingren Jingtong tablets, Wantong muscle and bone paste group and the group of experiments 1-3 have no obvious swelling on the right shoulder and have slight movement disadvantage.
The blood was drawn from each of 6 groups of New Zealand rabbits, and the 5-HT content, IL-1. beta. content and IL-10 content of the serum homogenate were measured, and the results were averaged, as shown in Table 1 below, and the following table was prepared as a histogram as shown in FIG. 1.
TABLE 1
As can be seen from fig. 1, in the treatment process of wind-cold-dampness scapulohumeral periarthritis, the minren neck pain tablet and the wantong bone and muscle patch have better effects than the medicines described in examples 1,3 and 4, and statistical analysis shows that the data of 5-HT content, IL-10 content, the minren neck pain tablet group and the experiment 1-3 group have no significant difference (P >0.05) with the wantong bone and muscle patch group, but the data of the wantong bone and muscle patch group have no significant difference (P >0.05) with IL-1 beta content, the wantong bone and muscle patch group has no significant difference with the minren neck pain tablet and muscle patch group and the experiment 1 group, but the data of the wantong bone and muscle patch group has significant difference (P <0.05) with the experiment 2 and 3 groups.
The effect of the Mingren Jingtong tablet is similar to that of the pharmaceutical composition in the prior art, and is superior to that of the Wantong muscle and bone paste in the prior art in treatment of wind-cold-dampness scapulohumeral periarthritis, so that the Mingren Jingtong tablet is also a blood-activating and stasis-removing medicine, the treatment effect on the scapulohumeral periarthritis is good and bad, and the Mingren Jingtong tablet and the pharmaceutical composition in the disclosure have better treatment effect on the scapulohumeral periarthritis obviously.
Example 6
Establishing a diabetic scapulohumeral periarthritis animal model:
150 SD male rats aged three months old (considering that part of rats cannot increase blood sugar due to their constitutions and part of rats die directly) are selected, and each rat weighs 25 g. Of these, 20 were randomly selected as the backup control group and 130 were selected as the backup experimental group.
For the spare experimental groups: after 130 rats in the standby experimental group are fasted for 12 hours, weighing the rats respectively, and taking blood from tail veins to measure blood sugar;
preparing a buffer solution: dissolving 2.1g of citric acid in 100ml of water, and filtering to obtain 28ml of solution A; dissolving 2.9g of sodium citrate in 100ml of water, filtering, taking 22ml of (solution B), mixing the solution A and the solution B, adding 50ml of water, and cooling in an ice bath;
the model group was injected intraperitoneally with STZ at a dose of 65 mg/kg: taking the citric acid buffer solution, dissolving STZ in the buffer solution, filtering with a 0.2um filter, and performing intraperitoneal injection; the animals were weighed after 72 hours of injection, blood was taken from the tail vein to measure the blood glucose level, and 60 model animals (STZ rats) with fasting blood glucose > 7.ommol/L and postprandial blood glucose > 15.ommol/L were randomly selected and retained for the experiments. Thereafter, blood glucose was weighed and measured weekly, and the experiment was started 8 weeks after the animals were kept.
For the spare control group, the rats were normally bred, and after 8 weeks, 10 rats in the spare control group were randomly selected as the control group to start the experiment.
The blood sugar level of 60 experimental rats is obviously increased to 23.7-32.6mmol/L from 3.2-5.0 mmol/L; the weight is reduced, the blood sugar level of the animals in the control group is not obviously changed, the weight is increased, and the model is established.
60 SD rats are divided into 6 groups, each group comprises 10 SD rats, and the 6 groups comprise a control group, an Angelica keiskei Koidz neck pain tablet group, a Wantong muscle and bone patch group, an experiment 1 group, an experiment 2 group and an experiment 3 group.
The 6 test groups were treated in the same manner as in example 5.
After 2 weeks, the above 6 groups were subjected to index detection in the same manner as in example 5
The observations after 2 weeks were as follows:
general condition observation is carried out to find that: the right forelimb of the control group was obviously impaired in activity, reduced in activity, and inappetence, all new zealand rabbits began to have a hair-loss phenomenon, and right shoulders were swollen, wherein two rabbits were swollen at various parts throughout the body, and 2 rabbits had fever symptoms. The Wantong muscle and bone paste group has slight disadvantaged activity to the rabbits, obvious swelling does not appear on the right shoulders of the Mingren neck pain tablet group and the experiment 1-3 groups, and the New Zealand rabbits move as usual. The blood was drawn from each of 6 groups of New Zealand rabbits, and the PGEZ content of the serum homogenate, the 5-HT content of the serum homogenate, the IL-1. beta. content of the serum homogenate, and the IL-10 content of the serum homogenate were measured, and the results were averaged as shown in Table 2 below, which was prepared as a bar graph as shown in FIG. 2.
TABLE 2
As can be seen from fig. 2, the pharmaceutical composition of experiment 1 group had far better effect than other groups in the treatment of diabetic scapulohumeral periarthritis. Through statistical analysis, the data in the experiment 1 group has obvious difference (P <0.05) with the group of the Mingren Jingtongtao tablets, and the group of the Mingren Jingtongtao tablets has no obvious difference (P >0.05) with the Wantong muscle and bone patch group. Obviously, in the treatment of the diabetes type scapulohumeral periarthritis, the minren cervicodynia tablet and the Wantong muscle and bone paste have the old effect on the treatment of the scapulohumeral periarthritis, but are far inferior to the pharmaceutical composition described in the experiment 1 group. It can be seen that the pharmaceutical composition of the present disclosure plays a greater role in the treatment of diabetic scapulohumeral periarthritis.
In addition, as can be seen from fig. 1-2, the pharmaceutical composition described in example 1 has better effect than the pharmaceutical compositions described in examples 3 and 4, and it can be seen that the grinding of notoginseng and chuanxiong rhizome together has a matching relationship, and probably the two promote the separation of the components of each other during the grinding process, which is beneficial for the drug to act. And the inventor thinks that the effect of the white paeony root is possibly conflicted in the process of matching the cold medicament and the warm medicament, and the white paeony root is decocted by the extraction waste water of the notopterygium root and the clematis root, so that the cold property of the white paeony root is slightly neutralized, and the absorption of the medicaments by a patient is facilitated.
The above disclosure is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the scope of the present invention, therefore, the present invention is not limited by the appended claims.
Claims (10)
1. The application of a pharmaceutical composition in preparing a medicine for treating scapulohumeral periarthritis is characterized in that the pharmaceutical composition is as follows: 1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber, 3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae and 4-25 parts of notopterygium root;
or 2-10 parts of pseudo-ginseng, 5-15 parts of ligusticum wallichii, 3-10 parts of corydalis tuber, 5-15 parts of radix paeoniae alba, 8-20 parts of radix clematidis, 5-15 parts of radix puerariae and 8-20 parts of notopterygium root;
or 2-3 parts of pseudo-ginseng, 7-8 parts of ligusticum wallichii, 5-6 parts of corydalis tuber, 7-8 parts of radix paeoniae alba, 10-11 parts of radix clematidis, 7-8 parts of radix puerariae and 10-11 parts of notopterygium root;
or 2.3 parts of pseudo-ginseng, 7.6 parts of ligusticum wallichii, 5.4 parts of corydalis tuber, 7.6 parts of white paeony root, 10.5 parts of clematis root, 7.6 parts of kudzu root and 10.5 parts of notopterygium root.
2. The use of the pharmaceutical composition of claim 1 in the preparation of a medicament for the treatment of scapulohumeral periarthritis, wherein the preparation method of the pharmaceutical composition comprises:
(1) firstly, the pseudo-ginseng is crushed into 100-mesh and 120-mesh fine powder;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, collecting the distilled water solution in another container, decocting the residue with water for 1 hr, and filtering to obtain filtrate;
(3) decocting radix Puerariae and radix Paeoniae alba with water twice (2 hr for the first time and 1 hr for the second time), mixing the filtrate with the above two water solutions, concentrating, precipitating with ethanol, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(4) reflux-extracting rhizoma Ligustici Chuanxiong and rhizoma corydalis with ethanol, removing residue, recovering ethanol from the extractive solution, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(5) mixing the above two fluid extracts, adding Notoginseng radix powder, mixing, drying, pulverizing into fine powder, adding appropriate amount of rhizoma Peucedani, mixing, and spraying the volatile oil of Notopterygii rhizoma and radix Clematidis.
3. The pharmaceutical composition for treating scapulohumeral periarthritis is characterized by comprising the following components in parts by weight: 15-45 parts of pseudo-ginseng, 8-30 parts of ligusticum wallichii, 2-7 parts of corydalis tuber, 3-7 parts of white paeony root, 5-11 parts of clematis root, 5-9 parts of kudzu root and 4-25 parts of notopterygium root.
4. The pharmaceutical composition for treating scapulohumeral periarthritis is characterized by comprising the following components in parts by weight: 20-40 parts of pseudo-ginseng, 10-20 parts of ligusticum wallichii, 3-5 parts of corydalis tuber, 5-7 parts of radix paeoniae alba, 9-10 parts of radix clematidis, 5-7 parts of radix puerariae and 4-17 parts of notopterygium root.
5. The pharmaceutical composition for treating scapulohumeral periarthritis is characterized by comprising the following components in parts by weight: 25-35 parts of pseudo-ginseng, 10-15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6-7 parts of radix paeoniae alba, 9 parts of radix clematidis, 6-7 parts of radix puerariae and 9-10 parts of notopterygium root.
6. The pharmaceutical composition for treating scapulohumeral periarthritis is characterized by comprising the following components in parts by weight: 30 parts of pseudo-ginseng, 15 parts of ligusticum wallichii, 4 parts of corydalis tuber, 6 parts of white paeony root, 9 parts of clematis root, 6.3 parts of kudzu root and 9.7 parts of notopterygium root.
7. A method for preparing a medicinal composition for treating scapulohumeral periarthritis is characterized by comprising the following steps: the method comprises the following steps:
(1) grinding Notoginseng radix and rhizoma Ligustici Chuanxiong together;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, and collecting the distilled water solution in another container;
(3) decocting the white paeony root with the water solution distilled in the step (2), and collecting and concentrating filtrate for later use;
(4) extracting radix Puerariae and rhizoma corydalis with water, and removing residue;
(5) mixing the filtrate and the extraction product obtained in the steps (3) and (4), concentrating, and precipitating with ethanol;
(6) and (3) uniformly mixing the fine powder in the step (1) with the clear paste in the step (5), and spraying the volatile oil of the notopterygium root and the clematis root extracted in the step (2) to obtain the traditional Chinese medicine.
8. The method for preparing a pharmaceutical composition for the treatment of scapulohumeral periarthritis according to claim 7, wherein: in the step (1), the pseudo-ginseng and the szechuan lovage rhizome are crushed into 100-mesh 120-mesh fine powder.
9. The method for preparing a pharmaceutical composition for the treatment of scapulohumeral periarthritis according to claim 7, wherein: in the step (3), the white paeony root is cut into small blocks and decocted for 4-4.5 hours.
10. The method for preparing a pharmaceutical composition for the treatment of scapulohumeral periarthritis according to claim 7, wherein: in the step (5), the concentrated solution is made into clear paste with the relative density of 1.50-1.55 at 50 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010738543.9A CN111888395A (en) | 2020-07-28 | 2020-07-28 | Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010738543.9A CN111888395A (en) | 2020-07-28 | 2020-07-28 | Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111888395A true CN111888395A (en) | 2020-11-06 |
Family
ID=73182223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010738543.9A Pending CN111888395A (en) | 2020-07-28 | 2020-07-28 | Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111888395A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022160548A1 (en) * | 2021-01-29 | 2022-08-04 | 山东明仁福瑞达制药股份有限公司 | Ointment for treating cervical spondylotic radiculopathy and preparation method therefor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446569A (en) * | 2003-03-24 | 2003-10-08 | 于少华 | Medicament for treating cervical spondylosis and preparation method thereof |
-
2020
- 2020-07-28 CN CN202010738543.9A patent/CN111888395A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446569A (en) * | 2003-03-24 | 2003-10-08 | 于少华 | Medicament for treating cervical spondylosis and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 康爱多网上药店: "颈痛颗粒对颈椎 肩周炎效果怎么样 功能主治什么", 《HTTPS://WWW.360KAD.COM/MEDICATION/511399.SHTML》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022160548A1 (en) * | 2021-01-29 | 2022-08-04 | 山东明仁福瑞达制药股份有限公司 | Ointment for treating cervical spondylotic radiculopathy and preparation method therefor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104398431B (en) | It is a kind of to treat Chinese medicine extract product of chloasma and preparation method thereof | |
| CN101444611A (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN111888395A (en) | Pharmaceutical composition, preparation method thereof and application thereof in scapulohumeral periarthritis treatment | |
| CN101310737A (en) | Medicine for treating ischemic stroke and its preparation method | |
| CN100339068C (en) | Dripping pill for treating coronary heart disease and preparing method | |
| CN111184792A (en) | Traditional Chinese medicine composition for treating knee osteoarthritis | |
| CN100509010C (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| WO2022272314A1 (en) | Medicine composition for treatment of bone and joint diseases originated from medicinal materials and the process for producing thereof | |
| CN101450189B (en) | Medicine for curing angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN104707023A (en) | Traditional Chinese medicinal composition for treating polycystic ovary syndrome, and preparation method thereof | |
| CN106853021A (en) | Prevent and treat Chinese medicine composition of CKD and its preparation method and application | |
| CN113244366A (en) | Traditional Chinese medicine composition for treating premature ejaculation and impotence and preparation method and application thereof | |
| CN101342346A (en) | Drop pill for treating stenocardia caused by coronary disease | |
| CN102048966A (en) | Chinese medicinal preparation for treating diabetes and preparation method thereof | |
| CN117815350B (en) | Traditional Chinese medicine composition for treating coronary artery myocardial bridge and application thereof | |
| CN100441208C (en) | Bolus for treating rheumatic or rheumatoid arthritis and its preparation method | |
| CN115177690B (en) | Traditional Chinese medicine composition for treating osteoarthritis and preparation method thereof | |
| CN114869956B (en) | Pharmaceutical composition for treating post-stroke dyskinesia, and preparation method and application thereof | |
| CN102631625B (en) | Shenqi capsule and preparation method thereof | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN103720943B (en) | A kind of Chinese medicine for the treatment of gynecological bleeding and preparation method thereof | |
| CN108310207B (en) | Pharmaceutical composition for treating heart failure and preparation method thereof | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN111000902B (en) | Traditional Chinese medicine tincture for treating acute soft tissue injury and preparation method thereof | |
| CN108066448B (en) | Composition with functions of relieving physical fatigue and enhancing immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Yujuan Inventor after: Liu Jie Inventor after: Xu Min Inventor after: Gao Chao Inventor after: Pan Ruixue Inventor after: Wang Li Inventor after: Zhang Yaxin Inventor after: Chen Kexin Inventor after: Hao Honghui Inventor before: Jiang Yujuan Inventor before: Liu Jie Inventor before: Xu Min Inventor before: Gao Chao Inventor before: Pan Ruixue Inventor before: Wang Li Inventor before: Zhang Yaxin Inventor before: Chen Kexin Inventor before: Hao Honghui |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201106 |